For the Inventor, By the Inventor

Enter assignee name

Westlake Village, CA, United States of America

Mannkind Corporation

USPTO Granted Patents = 278

CIPO Patents = 20

EPO Patents = 76

Trademarks = 40

Forward Citations = 4,683

Loading Chart...

Loading Chart...

148 inventors (with patents filed for the assignee):

Chad C Smutney (63 out of 74 patents)

Benoit Adamo (58 out of 88 patents)

P Spencer Kinsey (55 out of 70 patents)

4. John M Polidoro (37 out of 62 patents)

5. Marshall L Grant (33 out of 33 patents)

6. Carl R Sahi (28 out of 47 patents)

7. Solomon S Steiner (26 out of 58 patents)

8. Kelly Sullivan Kraft (22 out of 27 patents)

9. Trent A Poole (22 out of 38 patents)

10. John J Freeman (21 out of 34 patents)

11. Dennis Overfield (20 out of 20 patents)

12. Scott McLean (19 out of 88 patents)

13. Bryan R Wilson (19 out of 24 patents)

14. Andrea Leone-Bay (18 out of 118 patents)

15. Per B Fog (18 out of 18 patents)

Core Competencies:

Fluid Delivery Device

Dry Powder Inhaler

Diketopiperazine Microparticles

Ultrarapid Acting Insulin

Cryogranulation Apparatus

Pharmaceutical Composition

Drug Delivery System

Obesity Treatment

Diabetes Management

Hydraulically Actuated Pump

Prodrugs of Treprostinil

Inhalable Pharmaceutical Composition

278 patents: Sort by Forward Citations

1. 12508376 - Dry powder inhaler (2025-12-30),

2. 12465681 - Cartridge insertion mechanism for a fluid delivery device (2025-11-11),

3. 12459903 - Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine (2025-11-04),

4. 12453702 - Apparatus and method for cryogranulating a pharmaceutical composition (2025-10-28),

5. 12447293 - Dry powder inhaler and system for drug delivery (2025-10-21),

6. 12440620 - Moving basal engine for a fluid delivery device (2025-10-14),

7. 12433889 - Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them (2025-10-07),

8. 12383552 - Diketopiperazine microparticles with defined specific surface areas (2025-08-12),

9. 12370137 - Method and composition for treating obesity (2025-07-29),

10. 12357599 - Prodrugs of treprostinil (2025-07-15),

11. 12303554 - Use of ultrarapid acting insulin (2025-05-20),

12. 12246159 - Multi-cartridge fluid delivery device (2025-03-11),

13. 12233206 - Dry powder inhaler and system for drug delivery (2025-02-25),

14. 12202807 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2025-01-21),

15. 12168114 - Fluid delivery device having an insertable prefilled cartridge (2024-12-17),

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for patients with diseases such as diabetes. Their flagship product, Afrezza, is an inhaled insulin used to improve glycemic control in adults with diabetes mellitus. MannKind Corporation strives to advance healthcare solutions through innovative and accessible treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

278 Patents

#1 in Westlake Village, CA

#331 in California

#1,500 in US

#3,078 in the World

Westlake Village, CA, United States of America

Mannkind Corporation

Forward Citations = 4,683

148 inventors:

Chad C Smutney (63 out of 74 patents)

Benoit Adamo (58 out of 88 patents)

P Spencer Kinsey (55 out of 70 patents)

4. John M Polidoro (37 out of 62 patents)

5. Marshall L Grant (33 out of 33 patents)

Please report any incorrect information to support@idiyas.com

Loading…